Table 2: Univariate comparison between responders and non-responders.
|
Clinical and disease-related features |
Responders (TRS 0-2) |
Non-responders (TRS 3) |
P-value |
|
|
N = 34 (47.2%) |
N = 38 (52.8%) |
|||
|
Gender |
Male |
22 (64.7%) |
22 (57.9%) |
0.554 |
|
Female |
12 (35.3%) |
16 (42.1%) |
||
|
Mean age (years) |
63.08 ± 13.87 |
63.18 ± 11.44 |
0.668 |
|
|
Pre-operative staging |
Stage 1 |
1 (2.9%) |
0 (0%) |
0.894 |
|
Stage 2 |
16 (47.1%) |
19 (50%) |
||
|
Stage 3 |
17 (50%) |
19 (50%) |
||
|
Radiotherapy |
Short course |
3 (8.8%) |
4 (10.5%) |
0.808 |
|
Long course |
31 (91.2%) |
34 (89.5%) |
||
|
Surgical approach |
Lap (intent to treat) |
23 (67.7%) |
25 (65.8%) |
0.86 |
|
Open |
11 (32.3%) |
13 (34.2%) |
0.86 |
|
|
Lap converted to open |
1 (2.9%) |
8 (21%) |
0.02 |
|
|
Post-operative staging |
Stage 0 |
12 (35.3%) |
0 (0%) |
0.0001 |
|
Stage 1 |
9 (26.5%) |
11 (28.9%) |
0.815 |
|
|
Stage 2 |
8 (23.5%) |
17 (44.7%) |
0.059 |
|
|
Stage 3 |
5 (14.7%) |
10 (26.3%) |
0.226 |
|
|
Adjuvant chemotherapy |
Yes |
12 (35.3%) |
19 (50%) |
0.208 |
|
No |
22 (64.7%) |
19 (50%) |
||
|
Mean follow-up (months) |
|
59.97 ± 48.70 |
58.76 ± 36.76 |
0.914 |